Orphazymes Drug for Niemann-Pick Disease Shows Promising Results in Phase 3 Trial

Orphazymes reported positive data from its Phase 3 trial of a drug for Niemann-Pick disease, a lysosomal storage disorder that severely impacts neurological function. (September 2, 2024)